AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01048645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
Study NCT01048645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
Study NCT01993017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.~CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement .
Study NCT01993017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Medication
Description: The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated.
Study NCT01993017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
Study NCT01993017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depressive symptom screener
Description: 8-item Patient Health Questionnaire, PHQ-8
Study NCT01993017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Depressive symptom screener
Description: 8-item Patient Health Questionnaire, PHQ-8
Study NCT01993017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Study NCT00811447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 600 mg/m²/day intravenous
Study NCT00811447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 600 mg/m²/day intravenous
Study NCT00811447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m² or 75 mg/m² intravenous
Study NCT00811447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 60 mg/m² or 75 mg/m² intravenous
Study NCT00811447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m² intravenous
Study NCT01240954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OSIRIS
Description: OSIRIS current practice
Study NCT01240954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSIRIS other concentration 1
Description: OSIRIS new concentration 1
Study NCT01240954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSIRIS other concentration 2
Description: OSIRIS new concentration 2
Study NCT00694382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study NCT00694382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for semuloparin)
Description: 0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study NCT06089252 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: walnut extract
Description: Four times a day over a 10-day period
Study NCT04463121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moderato IPG's CNT pacing signals
Description: Assesment of cardiac function and sympatheric activity will be obtained simultaneously
Study NCT04463121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD Leycom Pressure/Volume Combination Catheters
Description: Simultaneous recording of the Pressure, Volume measurements and ECG signals will be done for constant monitoring of intra-ventricular pressure and volume.
Study NCT04328402 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Polysomnography, referred to as type I, allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables to document tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial and other muscular activity during sleep. The apnea and hypopnea index (AHI) is defined as the number of obstructive apneas and hypopneas per hour of sleep. Obstructive Sleep Apnea is defined in PSG when AHI≥1 and is divided into the following categories, according to severity: mild OSA (AHI 1-4.9), moderate OSA (AHI 5-9.9) and severe OSA (IAH≥10). Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or episodes are greater than or equal to 4 (high frequency SB, severe bruxism).
Study NCT01396577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perampanel
Description: 3 x 2 mg perampanel once per day
Study NCT01396577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perampanel
Description: 6 mg perampanel once per day
Study NCT03117725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin adminstration
Description: The drug, melatonin will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
Study NCT03117725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo administration
Description: the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
Study NCT03899961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 2.5 U i.v.
Study NCT03899961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Carbetocin 100 µg i.v.
Study NCT02057601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration group
Description: The patients in the intervention group will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
Study NCT00939731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules
Study NCT00939731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets
Study NCT03634501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated NK
Description: Cell suspension
Study NCT01047644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced port-flush schedule
Description: 3-month port-flushing
Study NCT01861821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiport flexible catheter
Description: Multiport flexible catheter has three ports for the delivery of epidural medication
Study NCT01861821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uniport flexible catheter
Description: Uniport flexible catheter has one port for the delivery of epidural medication
Study NCT01042743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted surgery
Description: da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
Study NCT01042743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic right-hemicolectomy
Description: Conventional laparoscopic procedures
Study NCT03437590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942
Description: JNJ-55308942 will be administered as oral solution.
Study NCT03437590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-JNJ-64413739
Description: \[18F\]-JNJ-64413739 fluid for injection administered intravenously.
Study NCT01927679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin E
Study NCT01927679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eucerin
Description: Control
Study NCT03620721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness
Description: 8-week mindfulness based group intervention
Study NCT03322826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: systematic sampling of the lymph-node
Description: Systematic Sampling of lymph nodes
Study NCT03322826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymphadenectomy
Description: Routine lymph nodes dissection in lung cancer
Study NCT00509418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid
Description: Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks
Study NCT00509418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric Diet with controlled exercise
Description: Modified ADA diet in combination with controlled exercise daily 24 weeks
Study NCT01356953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Intensity of aerobic exercise
Study NCT03708588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Chewed
Study NCT03708588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Integral
Study NCT02757482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training
Study NCT03971838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Outcomes for Women
Description: Women and their children 10+ can consent to participate in the diabetes prevention programming offered through the research center. We will collect data at three time points, baseline, 4-6 months, and 12 months.~2. Instead of participating in Encourage, women may participate in other diabetes prevention programming/weight management programming offered by other entities. Researchers will consent these women into the study to complete 3 data collection points, baseline, 4-6 months, and 12 months. Additionally, researchers will consent women to obtain data from their chosen program. For instance, if a woman chooses to do a Diabetes Prevention Program through the YMCA, researchers will ask women to self report their weekly attendance and weight.
Study NCT04712201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En bloc transurethral resection of bladder tumor (TURBT)
Description: En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy
Study NCT04712201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TURBT
Description: Conventional transurethral resection of bladder tumor using monopolar and bipolar energy
Study NCT03570983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
Study NCT03570983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
Study NCT03570983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.
Study NCT03570983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.
Study NCT03570983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3. Availability and administration: Cytarabine is available in a reconstituted form in solutions containing 20, 50 and 100 mg of cytarabine per mL.
Study NCT03570983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
Study NCT00891306 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
Description: intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
Study NCT00891306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: oral, 2 g/day, day -3 till week 12
Study NCT00891306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: oral, 3 mg/kg/day, day -3 till week 12
Study NCT00891306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
Study NCT01391325 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Allopurinol
Description: Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
Study NCT00603265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859
Study NCT00603265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Study NCT00603265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00603265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03131635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developmental Reciprocity Treatment Program (DRT-P)
Description: Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
Study NCT03102125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: For use in stress myocardial perfusion imaging.
Study NCT02966002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT05340751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood drawn
Description: Hemoglobin and Hematocrit Levels
Study NCT03311763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIM Fitness Practitioners
Description: Exercise is Medicine Practitioners will facilitate peer groups that attend twice-weekly exercise classes for 8 weeks, with clinical monitoring and advise regarding increasing physical activity.
Study NCT03311763 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling and wearable device
Description: Brief exercise counseling session and provision of a wearable fitness tracking device to promote physical activity.
Study NCT03311763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling and wearable device
Description: Brief exercise counseling session and provision of a wearable fitness tracking device to promote physical activity.
Study NCT02110732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus rhamnosus GG
Study NCT02110732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus rhamnosus GG
Study NCT01073800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 80 mg per os daily
Description: atorvastatin 80 mg per os daily
Study NCT01073800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02425748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: DC-CIK cells will be used against tumor cells.
Study NCT02425748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T Cell
Description: γδ T cells will be used against non small lung tumor.
Study NCT02425748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T/DC-CIK cells
Description: γδ T/DC-CIK cells will be used against lung tumor.
Study NCT02825901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Ingest placebo drink 100ml/day for 8 weeks
Study NCT02825901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Djulis-Buckwheat
Description: Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks
Study NCT02825901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Djulis-Buckwheat
Description: Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks
Study NCT02825901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Buckwheat
Description: Ingest Buckwheat drink 100ml/day for 8 weeks
Study NCT02825901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buckwheat
Description: Ingest Buckwheat drink 100ml/day for 8 weeks
Study NCT00039325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell-MART-1 peptide vaccine
Description: Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
Study NCT03491345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: avelumab 10mg/kg, IV, q 2 weeks
Study NCT03497507 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham bracelet
Description: Patients will wear bracelets on both hands
Study NCT03497507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure bracelet
Description: Patients will wear bracelets on both hands.
Study NCT03313102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: sample of 16 blood tubes
Study NCT01656837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Community Treatment
Study NCT01656837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MST-BSF
Study NCT02304965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily physical activity
Description: A combination of walking (> 10.000 steps per day) and cycling on a stationary bicycle at home at an individual intensity. For the activity walking patients need to walk at a certain speed (e.g. 3 km/h) in order to be in the range of pulsatility as obtained from their pre-training treadmill test. For cycling a defined power in watt and duration will be given to each patient as defined from the pre-training cycling test.
Study NCT01290211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: maraviroc 300 mg BID x 5 days
Study NCT01290211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir
Description: fosamprenavir/ritonavir 700/100 mg BID x 10 days
Study NCT01290211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Fosamprenavir/ritonavir
Description: maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
Study NCT01290211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: maraviroc 300 mg QD x 5 days
Study NCT01290211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir
Description: fosamprenavir/ritonavir 1400/100 mg QD x 10 days
Study NCT01290211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Fosamprenavir/ritonavir
Description: maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
Study NCT02282410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year.
Study NCT01919996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
Study NCT02111785 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burr Hole Craniostomy
Description: Treatment with surgical burr hole craniostomy and evacuation of SDH